Abstract
Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Developing Countries*
-
Drug Combinations
-
Drug Resistance, Multiple, Viral*
-
Drugs, Generic
-
Female
-
Genes, MDR
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV-1 / genetics
-
HIV-1 / physiology*
-
Humans
-
Lamivudine / blood
-
Lamivudine / therapeutic use
-
Male
-
Mali
-
Mutation
-
Nevirapine / blood
-
Nevirapine / therapeutic use
-
RNA, Viral / blood
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Stavudine / blood
-
Stavudine / therapeutic use
-
Treatment Failure
-
Viral Load
Substances
-
Drug Combinations
-
Drugs, Generic
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Nevirapine
-
Stavudine